摘要
目的揭示前列腺液(expressed prostatic secretion,EPS)中zeste增强子同源物2(enhancer of zeste homolog 2,EZH2)表达在前列腺癌(prostate cancer,PCa)诊断中的临床价值,为非损伤性PCa诊断提供新思路。方法收集苏州市第九人民医院2017年12月至2019年12月期间门诊及住院收治的前列腺炎(prostatitis,Ps)、良性前列腺增生(benign prostatic hyperplasia,BPH)和有前列腺穿刺指征的可疑PCa患者的EPS共100例。根据临床及病理结果分组,Ps组32例,BPH组33例,PCa组35例。招募苏州市第九人民医院2019年6月至2019年12月期间门诊的健康志愿者20名作为对照组。用RT-PCR及ELISA检测EPS中EZH2的表达水平。采用Spearman相关性分析对EPS中EZH2水平和临床病理特征之间的关系进行分析。采用受试者工作特征(receiver operating characteristic,ROC)曲线下面积分析EPS中EZH2在PCa诊断中的临床应用价值。结果PCa组EPS中EZH2的表达水平高于Ps组、BPH组和对照组(均P<0.05)。Ps组以及BPH组和对照组EPS中EZH2的表达水平比较,差异均无统计学意义(均P>0.05)。PCa患者EPS中EZH2表达水平在分化程度方面比较,差异具有统计学意义(P<0.05)。EPS EZH2 mRNA相对表达量在诊断PCa的ROC曲线下面积高于前列腺特异性抗原(0.966 vs 0.649)。当EPS EZH2 mRNA相对表达量≥0.55时,诊断PCa敏感度为97.1%,特异度为87.9%。结论PCa患者EPS中EZH2表达水平上调。EPS中EZH2表达水平诊断PCa具有较高的敏感度和特异度。
Objective To reveal the clinical value of enhancer of zeste homolog 2(EZH2)expression in expressed prostatic secretion(EPS)in the diagnosis of prostate cancer(PCa),and to provide a new idea for non-invasive diagnosis of PCa.Methods A total of 100 EPS samples from patients with prostatitis,benign prostatic hyperplasia(BPH),and suspected PCa with prostate puncture indication were collected from Suzhou Ninth People's Hospital from December 2017 to December 2019.According to clinical and pathological results,32 patients were in the prostatitis group,33 patients in the BPH group,and 35 patients in the PCa group.Twenty healthy examiners were re-cruited from Suzhou Ninth People's Hospital from June 2019 to December 2019 as the control group.EZH2 expression in EPS of different groups was detected by RT-PCR and ELISA.Spearman correlation was used to analyze the relationship between EZH2 expression in EPS and clinicopathological characteristics.The area under the receiver operating characteristic(ROC)curve was used to analyze the clinical application value of EZH2 in EPS in the diagnosis of PCa.Results The expression level of EZH2 in EPS of the PCa group was significant-ly higher than those of the prostatitis group,the BPH group and the control group(all P<0.05);while there was no significant difference in the expression of EZH2 in EPS between the prostatitis group and the BPH group and the control group(both P>0.05).The expression level of EZH2 in EPS of PCa patients was statistically significant in different pathological grades of PCa(P<0.05).The area under the ROC curve of the EPS EZH2 mRNA level for the diagnosis of PCa was significantly higher than that of prostate specific antigen level(0.966 vs.0.649).When the relative expression of EPS EZH2 mRNA was≥0.55,the sensitivity of diagnosing PCa was 97.1%,and the specificity was 87.9%.Conclusions The expression level of EZH2 in EPS was up-regulated in PCa patients.The expression level of EZH2 in EPS has high sen-sitivity and specificity for the diagnosis of PCa.
作者
王臻帆
徐辰
陈建春
马峥
蒋民军
Wang Zhenfan;Xu Chen;Chen Jianchun;Ma Zheng;Jiang Minjun(Department of Urology,Suzhou Ninth People’s Hospital,Suzhou Ninth Hospital Affiliated to Soochow University,Suzhou 215000,China)
出处
《实用肿瘤杂志》
CAS
2022年第3期248-252,共5页
Journal of Practical Oncology
关键词
前列腺癌
zeste增强子同源物2
前列腺液
诊断
prostate cancer
enhancer of zeste homolog 2
expressed prostatic secretion
diagnosis
